ResMed (RMD) came out with quarterly earnings of $2.55 per share, beating the Zacks Consensus Estimate of $2.49 per share. This compares to earnings of $2.2 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +2.41%. A quarter ago, it was expected that this maker of medical products for respiratory disorders would post earnings of $2.46 per share when it actually produced earnings of $2.55, delivering a surprise of +3.66%.Over the ...

Core Insights - Abbott reported quarterly earnings of $1.3 per share, matching the Zacks Consensus Estimate, and showing an increase from $1.21 per share a year ago [1] - The company posted revenues of $11.37 billion for the quarter ended September 2025, missing the Zacks Consensus Estimate by 0.24%, but up from $10.64 billion year-over-year [2] - Abbott's shares have increased by approximately 17.8% year-to-date, outperforming the S&P 500's gain of 13% [3] Earnings Performance - Over the last four quarters, Abbott has surpassed consensus EPS estimates two times [2] - The current consensus EPS estimate for the upcoming quarter is $1.49, with expected revenues of $11.75 billion, and for the current fiscal year, the estimate is $5.15 on revenues of $44.66 billion [7] Market Outlook - The sustainability of Abbott's stock price movement will largely depend on management's commentary during the earnings call [3] - The Zacks Rank for Abbott is currently 4 (Sell), indicating expectations of underperformance in the near future [6] - The Medical - Products industry, to which Abbott belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Core Insights - Neogen (NEOG) reported quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.05 per share, and down from $0.07 per share a year ago, representing an earnings surprise of -20.00% [1] - The company posted revenues of $209.19 million for the quarter ended August 2025, surpassing the Zacks Consensus Estimate by 2.96%, but down from $216.96 million year-over-year [2] - Neogen shares have declined approximately 52.1% year-to-date, contrasting with the S&P 500's gain of 14.8% [3] Earnings Outlook - The company's earnings outlook is crucial for investors, including current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The trend of estimate revisions for Neogen was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] - Current consensus EPS estimate for the next quarter is $0.08 on revenues of $210.41 million, and $0.32 on revenues of $818.26 million for the current fiscal year [7] Industry Context - The Medical - Products industry, to which Neogen belongs, is currently ranked in the top 26% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, ResMed (RMD), is expected to report quarterly earnings of $2.49 per share, reflecting a year-over-year increase of +13.2%, with revenues projected at $1.32 billion, up 7.9% from the previous year [9]

分组1 - ResMed reported quarterly earnings of $2.55 per share, exceeding the Zacks Consensus Estimate of $2.46 per share, and up from $2.08 per share a year ago, representing an earnings surprise of +3.66% [1] - The company achieved revenues of $1.35 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.87%, compared to $1.22 billion in the same quarter last year [2] - ResMed has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] 分组2 - The stock has gained approximately 21.3% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.2% [3] - The current consensus EPS estimate for the upcoming quarter is $2.49 on revenues of $1.32 billion, and for the current fiscal year, it is $10.46 on revenues of $5.52 billion [7] - The Zacks Industry Rank indicates that the Medical - Products sector is currently in the bottom 26% of over 250 Zacks industries, which may impact stock performance [8]

Core Insights - ResMed is positioned to continue its earnings-beat streak, having surpassed earnings estimates in the last two quarters by an average of 3.04% [1][5] - The company reported earnings of $2.36 per share for the most recent quarter, slightly below the expected $2.37, but still achieved a surprise of 0.42% [2] - In the previous quarter, ResMed exceeded the consensus estimate of $2.30 per share by reporting $2.43, resulting in a surprise of 5.65% [2] Earnings Estimates and Predictions - Recent estimates for ResMed have been increasing, with a positive Earnings ESP of +5.16%, indicating bullish sentiment among analysts regarding the company's earnings prospects [5][8] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a high likelihood of another earnings beat, with historical data showing that such combinations lead to positive surprises nearly 70% of the time [6][8] Earnings ESP Explanation - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [7] - A negative Earnings ESP can reduce predictive power but does not necessarily indicate an earnings miss [9] Importance of Earnings ESP - Companies often beat consensus EPS estimates, but this is not the only factor influencing stock price movements; thus, checking the Earnings ESP is crucial for investment decisions [10]

分组1 - ResMed reported quarterly earnings of $2.37 per share, exceeding the Zacks Consensus Estimate of $2.36 per share, and up from $2.13 per share a year ago, representing an earnings surprise of 0.42% [1] - The company achieved revenues of $1.29 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.53%, compared to $1.2 billion in the same quarter last year [2] - ResMed has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] 分组2 - The stock has declined approximately 6.4% since the beginning of the year, while the S&P 500 has decreased by 10.1% [3] - The current consensus EPS estimate for the upcoming quarter is $2.45 on revenues of $1.32 billion, and for the current fiscal year, it is $9.47 on revenues of $5.11 billion [7] - The Zacks Industry Rank for Medical - Products is in the bottom 26% of over 250 Zacks industries, indicating potential challenges for stock performance [8]